Charles Bankhead
BPH: Current, forthcoming modalities show efficacy
Four-year data on the prostatic urethral lift (UroLift) and data on a new water-jet ablation treatment were among BPH/LUTS highlights from this year’s meeting.
Statins linked with reduced prostate volume growth
Men taking statin drugs had a modest reduction in prostate growth in a new analysis of a 4-year, large, randomized trial of the dual 5-alpha-reductase inhibitor dutasteride (Avodart) versus placebo for risk reduction of prostate cancer among high-risk men.
PDE-5 inhibitor use shows no effect on BPH therapy outcomes
On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.
PDE-5 inhibitor, alpha-blocker each relieve LUTS/BPH symptoms
Men with moderate to severe lower urinary tract symptoms associated with BPH obtained significant symptom relief with the phosphodiesterase type-5 inhibitor tadalafil (Cialis) and the alpha-blocker tamsulosin (Flomax), both of which also improved urinary flow, results of a randomized trial showed.
Economic burden of kidney cancer eased by robotics
Adoption of robotic surgery for treatment of kidney cancer has led to a modest increase in the annual volume of partial nephrectomies but a substantial cost savings for care of chronic kidney disease, an economic analysis of a 6-year period suggests.
Partial nephrectomy shows no long-term benefit in elderly
Older patients with early-stage kidney cancer had significant improvement in short-term survival after partial versus radical nephrectomy but no long-term survival benefit, data from a large retrospective study showed.
Partial nephrectomy better than radical for survival
Patients with early-stage kidney cancer fared much better with partial rather than radical nephrectomy if they were candidates for either procedure, say researchers from the University of Michigan, Ann Arbor.
Neoadjuvant combo efficacious in high-risk prostate cancer
One-third of men with high-risk prostate cancer achieved pathologic complete response (pCR) or near-complete response to 6 months of preoperative therapy with abiraterone acetate (ZYTIGA), leuprolide, and prednisone, investigators reported at the American Society of Clinical Oncology annual meeting in Chicago.
Volume loss linked with post-nephrectomy function
Functional recovery after partial nephrectomy correlated more closely with volume loss than with warm ischemia time, researchers from Cleveland Clinic's Glickman Urological and Kidney Institute recently reported.
Robotic radical prostatectomy remains more costly than open technique
A robot-assisted laparoscopic radical prostatectomy costs 40% more than a retropubic radical prostatectomy, according to a review of hospital data from one state.